Dengue Vaccines Regulatory Pathways: A Report on Two Meetings with Regulators of Developing Countries

Richard Mahoney and colleagues summarize two recent meetings convened by the Pediatric Dengue Vaccine Initiative and the Developing Countries' Vaccine Regulators Network on regulatory issues that need to be addressed before licensing dengue vaccines.

• Publication year

  2011

• Venue

  PLoS Medicine

• Publication date

  2011-02-01

• Fields of study

  Medicine, Political Science

• Identifiers
  DOI 10.1371/journal.pmed.1000418PMID 21364969PMCID 3042996
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dengue and dengue hemorrhagic fever.

  2014cited by this paper
• High Dengue Case Capture Rate in Four Years of a Cohort Study in Nicaragua Compared to National Surveillance Data

  2010cited by this paper
• Dengue Incidence in Urban and Rural Cambodia: Results from Population-Based Active Fever Surveillance, 2006–2008

  2010cited by this paper
• Dengue surveillance in preparation for field vaccine trials.

  2009cited by this paper
• Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses

  2008cited by this paper
• "Guidelines for the clinical evaluation of dengue vaccines in endemic areas": summary of a World Health Organization Technical Consultation.

  2008influential reference
• Prospects for a dengue virus vaccine

  2007cited by this paper
• Development of New Tuberculosis Vaccines: A Global Perspective on Regulatory Issues

  2007cited by this paper
• Vaccines against dengue: a review of current candidate vaccines at advanced development stages.

  2007cited by this paper
• Multi-level analyses of spatial and temporal determinants for dengue infection

  2006cited by this paper
• Experiments in social responsibility

  2006cited by this paper
• Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand.

  2005cited by this paper
• Dengue and Dengue Hemorrhagic Fever, Brazil, 1981–2002

  2005cited by this paper
• Dengue and dengue hemorrhagic fever epidemics in Brazil: what research is needed based on trends, surveillance, and control experiences?

  2005cited by this paper
• Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children

  2004cited by this paper
• Risk factors and clinical features associated with severe dengue infection in adults and children during the 2001 epidemic in Chonburi, Thailand

  2004cited by this paper
• 7 – ECONOMICS OF VACCINES: FROM VACCINE CANDIDATE TO COMMERCIALIZED PRODUCT

  2003cited by this paper
• The Vaccine book.

  2003cited by this paper
• Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.

  2002cited by this paper
• Dengue and Dengue Hemorrhagic Fever

  1998cited by this paper
• Dengue

  1872cited by this paper

• Determining the efficacy of guppies and pyriproxyfen (Sumilarv® 2MR) combined with community engagement on dengue vectors in Cambodia: study protocol for a randomized controlled trial

  2017cites this paper
• Immunization in the Asia-Pacific Region

  2017cites this paper
• The Regulation Requirement of Dengue Vaccines

  2017influential citation
• Developing a dengue vaccine: progress and future challenges

  2014cites this paper
• Optimal control and numerical optimization applied to epidemiological models

  2014cites this paper
• Recent progress in dengue vaccine development

  2014cites this paper
• Application of an M-cell-targeting ligand for oral vaccination induces efficient systemic and mucosal immune responses against a viral antigen.

  2013cites this paper
• Helping each other regulate clinical trials: a network of vaccine regulators from developing countries

  2013cites this paper
• Immunization in the Asia-Pacific region

  2012cites this paper
• Detection and sequencing of defective viral genomes in C6/36 cells persistently infected with dengue virus 2

  2012cites this paper
• Conserved MHC class I-presented dengue virus epitopes identified by immunoproteomics analysis are targets for cross-serotype reactive T-cell response.

  2012cites this paper
• Implementing new health interventions in developing countries: why do we lose a decade or more?

  2012cites this paper
• A handful of 'antipoverty' vaccines exist for neglected diseases, but the world's poorest billion people need more.

  2011cites this paper
• Epidemiologie, Klinik und Prävention von Dengue in Südost-Asien und unter europäischen Reisenden

  2011cites this paper
• Dengue Vaccines: Challenge and Confrontation

  2011cites this paper
• From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.

  2011cites this paper